Alnylam Obtains Rights to RNAi Delivery Technology from The CBR Institute

11-May-2006

Alnylam Pharmaceuticals, Inc. announced that it has obtained rights to RNAi delivery technology developed in the laboratory of Professor Judy Lieberman from the CBR Institute for Biomedical Research, a Harvard Medical School Affiliate. The in-licensed technology may enable small interfering RNAs - or siRNAs, the molecules that mediate RNAi - to be targeted with an engineered monoclonal antibody to tumors and other cell types, thereby broadening the scope of Alnylam's delivery technologies for RNAi therapeutics. The in-licensed technology represents another potential approach for delivery of RNAi therapeutics with systemic administration.

Other news from the department science

Most read news

More news from our other portals